SUBJECT INDEX

Acetate
  as a causal factor in sclerosing peritonitis in CAPD, 241
  as a risk factor in producing abdominal complications in CAPD patients, 236
dialysis, effects on cardiac function, 181
lipid studies and cardiovascular mortality, 130
Acetohydroxamate, in the treatment of recurrent struvite stone formers, 469
Acute Renal Failure, see Renal Failure, Acute
Acute Tubular Necrosis, prognostic value of Hippuran uptake, 641
Adrenergic receptors, blockade and effect on K metabolism, 572
Age, as a factor leading to a modification of dialysis schedules, 120
Aldosterone
during beta-blockade, 572
in pregnancy induced hypertension, 520
in toxemia and effect of water immersion, 557
Alkaline Phosphatase, no effect on stopping oral aluminium hydroxide, 207
Allografts, see Transplantation
Allopurinol
  in calcium nephrolithiasis, 378
  in the treatment of calcium stone disease, 434
treatment for recurrent urinary calculi, 422
Alpha-2 Macroglobulin, as an immuno-regulatory protein, 297
Aluminium
effect on secretion of parathyroid hormone, 737
effective aluminium free phosphate binder, 725
in hyperparathyroidism, 737
in parathyroid glands, 737
non-aluminium containing phosphate binder, 725
relationship between plasma concentration and parathyroid weight in haemodialysis patients, 731
toxicity in haemodialysis patients, 719, 723
  Aluminium Associated Bone Disease, response to stopping aluminium hydroxide supplements, 207
  Aluminium Hydroxide
    aluminium toxicity from oral ingestion, 207
    requirements in haemodialysis patients, 719
    substitution with an aluminium free phosphate binder, 725
  Amiloride, combined with thiazide therapy in hypercalciuria, 383
  Amyloidosis
    adrenal insufficiency, 601
    clinicopathological correlations, 595
deposition in haemodialysis patients with carpal tunnel syndrome, 122
dialysis experience, 595
experience with CAPD, 601
in patients on long-term haemodialysis, 131, 134
long-term prognosis with replacement therapy, 602
prognosis in patients with systemic disease, 595
Anaemia
  relationship to hyperparathyroidism, 745
  relationship to lymphocyte function, 235
response to increased iron absorption after reduction in oral aluminium hydroxide, 723
role of hyperparathyroidism in haemodialysis patients, 739
Analgesic Nephropathy
  ultrasound findings, 669
  age at entry to renal replacement programme, 38
Anergy, as an index for pre-transplant blood transfusion, 338
Angiography, in the evaluation of renal artery stenosis, 538
Angioplasty
  coronary vascular, 175
treatment of renal artery stenosis, 538
Angiotensin
  binding sites on human platelets and leucocytes, 562
Angiotensin, continued
in experimental hypertension in
pregnant rats, 506
Angiotensin Converting Enzyme Inhibi-
tion, studies with enalapril in essential
hypertension, 577
Anti-diuretic hormone, see Vasopressin
Anti-lymphocyte globulin
and CMV infections, 270
hazard when combined with Cyclo-
sporin A, 705
Anti-thymocyte Globulin, in treatment
of transplant rejection, 362
Anticoagulation, efficacy of MD-805 in
haemodialysis, 144
Aortorenal bypass for chronic renal
artery occlusion, 587
Atherosclerosis of renal artery treated
by angioplasty, 544
Autoantibodies
in renal transplantation, 305
relationship to HLA type in renal
glycosuria, 681
Autoregulation, in pregnant rats with
experimental hypertension, 499
Azathioprine, combined with blood
transfusion to reduce incidence of
sensitisation, 260

Base Therapy, for stone disease in
patients with renal tubular acidosis,
473

Basement Membrane Glycoproteins,
changes in nephrotic serum
nephritis, 656

Beta-blockade
effect of a selective and non-selective
blocker on active renin and pro-
renin, 566
effect on erythrocyte sodium-
potassium co-transport, 507
effect on K metabolism, 572

Beta-cell function, C-peptide as an index
of function in CAPD patients, 195
Blind Patients, experience with CAPD,
700

Blood Group, effect of Lewis mismatch
and transplantation, 261

Blood Pressure
in toxaemia and effect of water
immersion, 557
response to enalapril and propranolol,
577

Blood Transfusion
anergic and reactive patients, 346
anergy as an index for pretransplant
transfusion, 338

Blood Transfusion, continued
donor specific transfusions, 260
effect of perioperative transfusion
on transplant survival, 291
effect on plasma suppressive activity,
297
effect on transplant graft survival, 253
induction of Suppressor T-cells, 349
influence of different transfusion
protocols on graft survival, 253
reduced requirement with reduction
in aluminium hydroxide intake, 719
reduced sensitisation with combined
transfusion and immunosuppres-
sion, 259, 260
risk of producing iron overload
depending on HLA status, 150
sensitisation following transfusion,
260

Blood Volume
in nephrotic syndrome, 607
measurement in nephrotic syndrome,
608
relationship between natriuresis and
toxaemia, 527
relationship with ADH in nephrotic
syndrome, 603

Bone, aseptic necrosis in children, 99
Bone Mineral Content, relationship to
urinary calcium excretion in calcium
stone formers, 460

Bromocriptine
development of tolerance, 160
effect on blood pressure in haemo-
dialysis patients with elevated
plasma prolactin, 156

Bromoethylamine hydrobromide, as a
means of inducing chemical medullec-
tomy, 546

Brushite
in hypercalciuria, 372
in urine stone formers, 445

C-peptide
clearance studies in CAPD patients,
195
kinetics following enteral or intra-
peritoneal administration in CAPD
patients, 195

Calcium Metabolism
dietary restriction and effect on oxal-
late metabolism, 401
differing effects of sodium and
potassium citrate on urinary
calcium excretion, 382
effect of diet, thiazides and allo-
purinol on urinary excretion, 434
Calcium Metabolism, continued
- effect of glycine and methionine supplements on urinary excretion, 407
- effect of pyridoxine therapy on urinary excretion, 417
- effect of Verapamil in preventing ischaemic injury in an experimental model, 650
- effects of increased sodium intake on urinary saturation, 384
- hypercalciuria, 374
- in idiopathic calcium nephrolithiasis, 450
- in stone formers during dietary calcium and oxalate restriction, 401
- phosphate therapy in absorptive hypercalciuria, 384
- relationship of parathyroid hormone to hypertension in experimental animals, 220
- relationship of urinary excretion to dietary protein, 411
- relationship to Vitamin D after transplantation, 213
- urine saturation in stone formers, 445
- Calcium Oxalate stone formers, 440
- Calcium Oxalate stones, thiazide prophylaxis, 477
- Calcium Phosphate, in urinary stone formation, 386
- Calcium Stone Disease, bone mineral content relationship to urinary calcium excretion, 460
- treatment by high fluid intake, 438
- tubular function and relationship to sodium intake, 455
- Captopril
- causing acute renal failure, 536
- dosage required in CRF, 530
- effect on cell membrane transport, 493
- haematological toxicity, 536
- induced deterioration in transplant function in patients with arterial stenosis, 325
- side effects, 530
- Cardiac Function, during haemodialysis in patients with coronary heart disease, 181
- Cardiovascular
- complications on short dialysis, 114
- coronary vessel angioplasty, 175
- low incidence of disease with long dialysis schedules, 122
- Cardiovascular, continued
- no difference in complication rate between long and short dialysis, 139
- stability during short dialysis, 143
- Carpal Tunnel Syndrome
- as a complication of long-term haemodialysis, 122, 130
- Catecholamines, in pregnancy induced hypertension, 520
- Cation exchange, using polymers charged with calcium or iron, 725
- Cefoxitin, in the treatment of infected stone disease, 469
- Cell Mediated Immunity
- in haemodialysis and CAPD patients, 190
- in haemodialysis patients, 338
- Cell membrane, inhibition of ATP activity in hypertension, 489
- Children
- aseptic bone necrosis, 99
- causes of death on renal replacement therapy, 91
- causes of graft failure, 98
- epidemiology of hypertension in Neapolitan school children, 551
- experience with CAPD, 93
- growth on renal replacement therapy, 101
- modes of treatment in selected countries, 82
- nitrogen balance and nutritional status during haemofiltration, 201
- nutritional status change after switching to haemofiltration from haemodialysis, 207
- survival on renal replacement therapy programmes, 84
- Cholecaliferol, see Vitamin D
- Chronic Renal Failure, see Renal Failure, Chronic
- Citrate
- differing effects of the sodium and potassium salt on urinary calcium excretion, 382
- effect in calcium nephrolithiasis, 373, 375
- renal stone formation, 382
- Coagulation, during dialysis with heparin and MD-805, 144
- Conn’s Syndrome
- relationship of blood pressure to renal function following surgical removal, 487
- sodium metabolism and hypertension, 484
Constipation, preventative value of new aluminium-free phosphate binder, 725

Continuous Ambulatory Peritoneal Dialysis
  acetate as a risk factor, 236
  bowel perforation, 236
  catheter insertion rate, 54
  cell mediated immunity, 190
  diverticular disease, 236
  effect on uraemic insulin resistance, 686
  endogenous peritonitis, 228
  eosinophilic peritonitis, 229
  experience in patients with amyloidosis, 601
  glucose, insulin and C-peptide kinetics following enteral or intraperitoneal administration, 195
  in children, 93
  in patients with end-stage renal failure due to diabetes mellitus, 700
  insulin requirements in diabetic patients, 703
  interval mortality and treatment change rates, Registry details, 32
  long-term survival, 700
  lymphocyte function, 230
  necrotising enteritis, 236
  patient survival, Registry details, 21
  peritonitis incidence, 55, 236
  reduction in incidence of peritonitis with new connector system, 223
  rehabilitation status of patients in the USA, 243
  sclerosing encapsulating peritonitis, 236
  severe abdominal complications, 236

Coronary Heart Disease, cardiac functional changes during long and short dialysis, 181

Crystal Formation, in renal stone formation, 386

Crystallisation inhibitors, in idiopathic calcium stone formers, 396, 440

Cyclosporin A
  differentiation between nephrotoxicity and rejection, 360
  effect on interleukin-2 production, 354
  in pancreatic transplantation, 711
  nephrotoxicity and recognition by FNAB, 356
  producing cortical infarction in experimental nephritis, 662
  toxicity following pancreatic transplantation, 705

Cyclosporin A, continued
  short course for the treatment of steroid resistant rejection, 367
  Cystine, stone formation, 373, 375
  Cystinuria
    bicarbonate therapy and subsequent calcium phosphate deposition, 433
    possible 'escape' phenomenon during treatment, 432
    treatment with Thiola, 427
  Cytomegalovirus Infection, 675
    relationship to ALG, 270
    relationship to transplant rejection episodes, 270
    selection of patients for treatment with hyperimmune globulin, 277
    serology, 278
    treatment of infection with hyperimmune globulin, 271

Delayed Cutaneous Hypersensitivity
  as a measure of cell mediated immunity, 338
  effect of blood transfusion, 338

Desferrioxamine, treatment for aluminium toxicity, 723

Diabetes Mellitus
  age at entry to renal replacement programme, 39
  effect of good glycaemic control on proteinuria, 697
  insulin requirements after starting CAPD, 703
  intraperitoneal insulin administration during CAPD, 700
  nephropathy and effect of intraperitoneal insulin administration, 692
  patient survival, Registry details, 19
  Registry details, 19, 21–26
  rehabilitation of patients on CAPD in the USA, 243
  relationship to renal glycosuria, 685
  survival on CAPD, 700
  treatment by pancreatic transplantation, 705, 711

Diabetic Nephropathy
  end-stage renal failure treated by CAPD, 700
  treatment by combined renal and pancreatic transplantation, 705
  treatment by pancreatic transplantation, 705, 711

Dialyser reuse, 47–53, 142

Dialysis
  after open heart surgery in end-stage renal failure patients, 169
Dialysis, continued  
membranes, neutrophil accumulation during dialysis, 186  
related symptoms, incidence on long dialysis schedules, 122  
schedules, experience with long dialysis 122  
schedules, experience with short dialysis, 111, 139  
Dicalcium phosphate dihydrate, in renal stone formation, 386  
Diet  
calcium restriction in hypercalciuria, 377  
in the treatment of calcium stone disease, 434  
sodium intake and renal handling in calcium stone formers, 455  
Distal Tubule  
sodium reabsorption in calcium stone formers, 455  
function in idiopathic calcium nephrolithiasis, 450  
Diuretic Therapy, thiazide in recurrent calcium stone formers, 477  
Diverticular Disease, complicating CAPD, 236  
Donor-specific Blood Transfusion, effect on living related donor transplantation, 253  
Drug Sensitivity, interstitial nephritis, 646  

Education, relationship to CAPD training time, 243  
Enalapril  
effect on erythrocyte sodium-potassium co-transport, 507  
in essential hypertension, effect on GFR and renal haemodynamics, 577  
Encephalopathy, related to oral aluminium hydroxide, 207  
Eosinophilia, in drug-induced interstitial nephritis, 646  
Eosinophilic peritonitis, in CAPD, 229  
Epidemiology, of hypertension in Neapolitan children, 551  
Epitaxis, in crystal growth, 386  
Erythrocyte metabolism  
effect of age on sodium-potassium co-transport, 511  
sodium-potassium co-transport in hypertension, 507  
Erythropoiesis, relationship to lymphocyte function, 235  

Erythropoietin  
in patients with hyperparathyroidism, 745  
role in the anaemia of hyperparathyroidism haemodialysis patients, 739  
Ethylene Glycol, renal ultrastructural changes following acute poisoning, 636  
Euglycaemic Clamp, in the study of insulin resistance, 686  
Experimental Hypertension  
effect of chemical medullectomy, 546  
relationship between blood pressure and parathyroid hormone, 220  
renal sodium handling in pregnant rats, 499  
renal tubular function, 505  
Experimental Nephritis  
role of the immune system in progression, 623  
studies on effects of lipids and protein intake, 627  
Fc-receptors, blocking antibodies in renal transplantation, 305  
Ferritin  
as a marker of iron overload in haemodialysis patients, 150  
as an indicator of iron status, 154  
Fibrinogen, during dialysis with heparin and MD-805, 144  
Fibromuscular dysplasia, treated by percutaneous angioplasty, 538, 582  
Fine Needle Aspiration Biopsy combined with monoclonal antibody measurement of T-cell subsets during graft rejection, 309  
in differentiating between rejection and Cyclosporin A toxicity, 656  
Formation product, in stone formation, 396  
Free Fatty Acids, during dialysis with heparin and MD-805, 144  
Free Water Clearance, in calcium stone formers, 455  
Glomerular Basement Membrane, changes in nephrotoxic serum nephritis, 656  
Glomerular Filtration Rate during treatment with enalapril and propranolol, 577
Glomerular Filtration Rate, continued
   effect of protein intake, 410
Glomerular thrombosis, in experimental nephrisis is combined with CyA, 662
Glomerulonephritis
   age at entry to renal replacement programme, 37
   effect of protein on progression in experimental nephrisis, 627
   IgA complexes in IgA nephropathy, 617
   IgA nephropathy, immune complexes and the macrophage system, 610
   possible role of lipids in leading to progressive disease, 627
   producing acute renal failure and the predictive value of Hippuran uptake, 641
   recurrence in transplanted kidneys, 75
   recurrent after transplantation, Registry details, 33
   role of the immune system in progression in an experimental model, 623
   serum sickness model, and effect of CyA in experimental, 662
   studies on nephrototoxic serum nephritis in experimental, 656
   treatment of SLE by plasmapheresis, 629
Glucose Metabolism
   kinetics of enteral or intraperitoneal administration in CAPD patients, 195
   uraemic insulin resistance and effect of dialysis, 686
Glycine, effect on urinary oxalate excretion, 407
Glycolic acid, response of urinary excretion to pyridoxine therapy in oxalate stone formers, 417
Glycopeptides, as an inhibitor of calcification, 373
Glycosaminoglycans
   as an inhibitor of calcification, 373
   urinary excretion in idiopathic calcium stone formers, 440
Gout, as a cause of end-stage renal failure, Registry details, 41
Graft Rejection, see Rejection
Granuloma, in drug induced interstitial nephritis, 646
Growth, in children following transplantation, 101
Haemochromatosis alleles, influence on iron overload in haemodialysis patients, 150
Haemodialysis
   aluminium free phosphate binder, 725
   aluminium intoxication from oral aluminium hydroxide, 207
   amyloidosis as a long-term complication, 131, 134
   assessment of efficiency by measuring motor nerve conduction velocity, 130
   back-up support for CAPD patients, 700
   cardiac function in patients with coronary heart disease, 181
   cardiovascular stability during short dialysis, 143
   carpal tunnel syndrome as a long-term complication, 130, 134
   cell mediated immunity, 190, 338
   comparison to haemofiltration in children, 201
   dialyser reuse, 47–53, 143
   during open heart surgery, 174
   effect of length of treatment on immune responsiveness, 348
   effect of short dialysis on nerve function, 114
   effect on active and inactive renin, 514
   effect on plasma suppressive activity, 297
   effect on uraemic insulin activity, 686
   experience with long dialysis schedules, 122
   experience with short dialysis schedules, 111, 139
   hypertension and abnormal dopaminergic function, 156
   in patients with amyloidosis, 595
   incidence of non A–non B hepatitis, 675
   interval mortality and treatment change rates, Registry details, 30
   iron overload and HLA status, 150
   lymphocyte function, 230
   neutropenia, 186
   nutritional aspects of short dialysis, 114
   pericarditis incidence in long and short dialysis schedules, 132
   potassium metabolism during beta-blockade, 572
   pruritis incidence in long and short dialysis schedules, 133
   requirement for aluminium hydroxide therapy, 719

752
Haemodialysis, continued
response to Hepatitis B vaccination, 161
results of single-needle dialysis, 176
role of hyperparathyroidism in the
production of anaemia, 739
schedules, 111, 122, 139
secondary hyperparathyroidism, 731
studies of a new anticoagulant
MD-805, 144
treatment of acute renal failure,
Registry details, 68
Haemofiltration
improvement in nitrogen balance
and nutritional status in children,
201
place in overall dialysis strategy, 120
treatment for acute renal failure,
Registry details, 68
Haemoglobin, response to reduction in
aluminium hydroxide intake, 719
Haemolytic Uraemic Syndrome, as a
complication of CyA in experimental
serum sickness, 662
Henoch-Schönlein Syndrome, IgA
immune complexes and the
macrophage system, 610
Hepatic clearance, of immune complexes
in IgA nephropathy, 617
Hepatitis A, 61, 675
Hepatitis B, 61, 675
combined active and passive
immunisation, 167
effective titres after immunisation,
168
vaccination in patients and staff,
161
vaccination schedules, 167
Hepatitis non A--non B, 61, 675
Hereditary nephritis, age at entry to
renal replacement programme, 38
Heteropolyuronic acid, capacity to
absorb phosphate, 725
Hippuran, uptake in acute renal failure,
641
HLA Typing
in IgA nephropathy, 615
in renal glycosuria, 681
value in predicting iron overload in
haemodialysis patients, 150
HLA-matching, influence on outcome of
re-transplantation, 280
Homogenous precipitation, in stone
formation, 397
Hydroxycholecalciferol, see Vitamin D
Hydroxyapatite, in renal stone
formation, 386
Hydroxyproline, effect on urinary
oxalate excretion, 410
Hydroxyurea in the long-term manage-
ment of infected stone disease, 466
Hypercalciuria
aetiology, 374
in patients with calcium nephro-
liathiasis and normal serum calcium,
450
in patients with calcium stone
disease, 460
phosphate therapy for the absorptive
type III, 384
predisposing to renal stone disease,
372
therapeutic considerations, 376
Hyperoxaluria, association with
calcium nephrolithiasis, 373, 375
Hyperparathyroidism
aetiology of nodule formation, 736
after transplantation, 213
causing hypercalciuria, 374
effect on red cell survival, 745
in haemodialysis patients, 731
in the pathogenesis of anaemia in
haemodialysis patients, 739
thirst and haemodilution, 745
Hypertension, see also Experimental
Hypertension
as a cause of end-stage renal failure,
Registry details, 43
controlled trial of propranolol versus
enalapril in essential hypertension,
577
due to renal artery stenosis and
treatment by percutaneous angio-
plasty, 582
effect of beta-blockade on active
renin and prorenin, 566
endogenous digitalis-like substance
in essential hypertension, 489
epidemiology in Neapolitan children, 551
erythrocyte sodium-potassium
co-transport, 507
experimental in rats, 488
in pregnancy, 520
in renal artery stenosis and response to
percutaneous transluminal angi-
plasty, 538
Registry details, 43
sodium metabolism in essential
hypertension, 486
sodium retention in the aetiology of
essential hypertension, 493
use of Captopril in CRF, 530
Hyperuricosuria, association with calcium
nephrolithiasis, 373, 375
Idiopathic Hypercalciuria
calcium metabolism, 374
effect of calcium and oxalate
restriction on probability of
stone formation, 401
effect of pyridoxine therapy, 417
tubular function and relationship
to sodium intake, 455

Idiopathic Nephrolithiasis,
renal handling of inorganic phosphate,
treatment by diet, thiazides and
allopurinol, 434

IgA
clearance of complexes, 621
immune complexes in IgA
nephropathy, 617

IgA Nephropathy
HLA typing, 615
immune complexes and the
macrophage system, 610
immune complexes induced by diet, 617

Immune Complexes
dietary induced in IgA nephropathy,
in IgA nephropathy, 610
in the induction of experimental
serum sickness, 662
measurement, 614

Immune Responsiveness, changes with
length of time on haemodialysis, 348

Immune System, in the progression of
experimental nephritis, 623

Immunological basis of drug induced
interstitial nephritis, 646

Immunoregulation, role of plasma
suppressive activity, 297

Immunosuppression, protocols for
pancreatic transplantation, 705

Inactive Renin, see Renin

Inherited Disease, renal glycosuria, 681

Inhibition of crystallisation, 373

Inhibitors of stone formation, 396

Insulin
clearance studies in CAPD patients,
during beta-blockade, 572
effect of dialysis on uraemic
resistance, 686

intrapertitoneal administration and
effect on nephropathy, 692
intrapertitoneal administration in
diabetic patients on CAPD, 700
kinetics following enteral or intra-
pertitoneal administration in CAPD
patients, 195
resistance in uraemia, 686

Interleukin-2 (T-cell growth factor)
after blood transfusion, 349
during mixed lymphocyte reaction, 349
effect of CyA on production, 354

Interstitial Nephritis
Captopril related, 535
drug induced, 646

Interval Mortality
difficulty in determining following
transfer between modalities of
treatment, 73
in patients with stone disease and
hypertensive disease, Registry
analysis, 45

Analytical, Registry analysis, 28

Iron
oral supplements and aluminium
hydroxide therapy, 719

overload, influence of HLA type in
haemodialysis patients, 150

Laminin, urinary excretion in nephro-
toxic nephritis, 656

Lattice Ions, activities in crystallisation,
386

Leucocytes, binding sites for
angiotensin, 562

Lipid Metabolism, role in the progression
glomerulonephritis, 627

Liver
disease, iron and ferritin, 154
hepatic clearance of IgA complexes,
621

Lymphocyte Function
during viral infection, 265
effect of uraemic plasma, 297

Lymphocyte Transformation, in haemo-
dialysis and CAPD patients, 230

Macrophages, function in IgA
nephropathy, 610

Malignant Disease
as a cause of death of children on
dialysis, 108
incidence, Registry details, 56

Malignant Hypertension, as a cause of
end-stage renal failure, Registry
details, 43

Membranes, see Dialysis Membranes

Metastability, in hypercalciuria, 372

Methionine, effect on urinary oxalate
excretion, 407

Methylprednisolone, effect on
lymphoblastic transformation
in dialysis patients, 230

Micropuncture Studies, in pregnant rats
with experimental hypertension, 499
Nephrolithiasis, continued
possible pathogenetic role of amino acids, 407
role of dietary protein, 411
Nephrotic Syndrome, anti-diuretic hormone and impaired water excretion, 603
Nephrotoxic Nephritis, changes in the glomerular basement membranes, 623, 656
Nephrotoxicity
Cyclosporin A in pancreatic transplantation, 711
Cyclosporin A in transplant recipients, 356
Neuropathy, effect of short dialysis on motor nerve conduction velocity, 114
Neutral Proteinase
role in nephrotoxic serum nephritis, 656
urinary excretion in nephrotoxic nephritis, 656
Neutropenia, lung sequestration of neutrophils during haemodialysis, 186
Nitrofurantoin in the long-term management of infected stone disease, 466
Nitrogen Balance, of children on haemofiltration, 201
Noradrenaline, effect of bromocriptine in haemodialysis patients with elevated plasma prolactin, 156
Nucleation, as a first step in urinary crystal formation, 386
Nutritional Status
of children on haemofiltration, 201
of patients on short dialysis, 112, 114
Octacalcium phosphate in renal stone formation, 386
Open heart surgery in end-stage renal failure patients, 169
Orthophosphate, in hypercalcauria, 378
Osmolality in toxaemia and effect of water immersion, 557
Osteodystrophy, see Renal Osteodystrophy
Osteonecrosis, incidence following transplantation and relationship to pulse prednisolone, 331
Oxalate
bioavailability, 406
effect of amino acids on excretion, 410
Oxalate, continued
- effect of calcium and oxalate
  restriction on probability of stone
  formation, 401
- effect of diet, thiazides and allo-
  purinol on urinary excretion, 434
- effect of glycine and methionine
  supplements on urinary excretion,
  407
- excretion and calcium nephrol-
  lithiasis, 373, 375
- in relation to hypercalciuria, 372
- possibility that subclinical pyridoxine
  deficiency may lead to stone
  formation, 410
- response of urinary excretion to
  pyridoxine therapy in calcium
  oxalate stone formers, 417

Paediatric Patients, see children

Pancreas
- recognition of rejection in
  transplants, 709, 716
- transplantation in patients with
  diabetes mellitus, 705, 711

Parathyroid, histology in haemodialysis
- patients with severe secondary hyper-
  parathyroidism, 731

Parathyroid Hormone
- effect on erythrocyte sodium
  potassium co-transport, 512
- in idiopathic calcium nephrolithiasis,
  450
- no change in plasma concentration
  with amino acid supplements,
  407
- no effect on stopping oral aluminium
  hydroxide, 207
- relationship to parathyroid weight
  in haemodialysis patients, 731
- relationship to serum calcium after
  transplantation, 213
- role in the development of hyper-
  tension in experimental animals,
  220

Parathyroidectomy
- effect on blood pressure in experi-
  mental animals, 220
- incidence in patients on long and
  short dialysis schedules, 129
- in haemodialysis patients with severe
  secondary hyperparathyroidism,
  731
- response of anaemia, 739

Percutaneous angioplasty, in the treat-
ment of renovascular hypertension,
582

Perforation, bowel, as a complication of
CAPD, 236

Pericarditis, incidence during long and
short haemodialysis, 132

Peritoneal absorption, glucose, 195

Peritoneal Dialysis, see also CAPD
- treatment for acute renal failure,
  Registry details, 64

Peritonitis
- during CAPD, 700
- endogenous in CAPD, 228
- in CAPD patients, 236
- incidence in CAPD patients in the
  USA, 243
- incidence in CAPD patients with
  diabetes mellitus, 700
- reduction in incidence with new
  connector system, 223
- relationship to patient's age, 248
- relationship to patient's sex, 248
- sclerosing in CAPD, 241

pH, relationship to renal stone forma-
- tion, 374, 376

Phagocytosis, macrophage and monocyte
- in IgA nephropathy, 610

Phosphate
- changes following reduction of oral
  aluminium hydroxide, 723
- effect of reduced aluminium
  hydroxide intake in haemodialysis
  patients, 719
- effective control with aluminium free
  binder, 725
- efficacy of natural polymers in
  controlling plasma concentration,
  730
- relationship of urinary excretion to
  dietary protein, 411
- relationship to 1,25(OH)2 chole-
  calciferol after transplantation, 213
- renal threshold in patients with
  idiopathic nephrolithiasis, 450
- studies with aluminium free binder,
  725
- therapy in absorptive hypercalciuria,
  384
- therapy for stone disease in patients
  with renal tubular acidosis, 473

Phosphorus, urine saturation in stone
formers, 445

Plasma Volume, in pregnancy induced
hypertension, 520

Plasmapheresis
- in the treatment of SLE, 629
- in the treatment of steroid resistant
  transplant rejection, 362

Platelets, binding sites for angiotensin, 562
Poisoning, ultrastructural changes following ethylene glycol poisoning, 636
Polyarteritis, and recovery of renal function, 45
Polycystic Renal Disease, age at entry to renal replacement programme, 38
Potassium citrate, in hypocitraturic calcium nephrolithiasis, 378
effect of beta-blockade in haemodialysis patients, 572
erythrocyte co-transport in hypertension, 507
transmembrane transport in hypertension, 489
Pre-eclampsia, see Toxaemia
Pre-sensitised transplant recipients, risk factors on second and subsequent transplants, 280
Prednisolone in the pathogenesis of post-transplant osteonecrosis, 331
pharmacokinetics and pharmacodynamics in transplant patients, 286, 290
relationship between side-effects and pharmacokinetics, 286
therapy in children after transplantation, 106
Pregnancy effect of renal sodium handling and experimental animals, 499
effect of water immersion in normal and toxaemic patients, 557
hypertension and renin status, 520
influence on immune responsiveness, 347
Progesterone, effect on aldosterone, 528
Prognosis, determined by Hippuran uptake in acute renal failure, 641
Prolactin, effect on sympathetic activity and blood pressure of bromocriptine in haemodialysis patients with elevated plasma prolactin, 156
Proliferative Glomerulonephritis, in SLE and treatment by plasmapheresis, 629
Promoters of stone formation, 397
Propranolol in essential hypertension, effect on GFR and renal haemodynamics, 577
Pro-renin, effect of beta-blockade, 566
Prostaglandins, PGE₂, reduction following chemical medullectomy in experimental hypertension, 546
Protein, effect of dietary intake on urinary calcium, phosphate, urate and pH, 411
Proximal tubule function in calcium stone formers, 455
in idiopathic calcium nephrolithiasis, 450
Pruritus, during long and short dialysis schedules, 133
Pulmonary sequestration of neutrophils during haemodialysis, 186
Pyelonephritis age at entry to renal replacement programme, 38
relationship to hyperparathyroidism, 737
Pyridoxine deficiency in oxalate stone formation, 410
treatment in renal calcium oxalate calculi, 417
Pyrophosphate as an inhibitor of calcification, 373
urinary excretion in idiopathic calcium stone formers, 440
Recovery of renal function, Registry details, 45
Recurrent Stone Formation role of high calcium and phosphate excretion, 445
saturation and inhibition activities, 445
thiazide prophylaxis, 477
Red cell survival in hyperparathyroidism, 745
Registry Report acute renal failure, 64
Adult Report, 2—75
Continuous Ambulatory Peritoneal Dialysis (CAPD), 54
demographic data, 8
diabetes mellitus, 19, 21—26
dialyser reuse, 47
hepatitis, 61
interval mortality and treatment change rates, 28
malignant disease, 56
organisation of paediatric transplantation, 94
Paediatric Report, 79—108
patient survival, 13
recovery of renal function, 45
renal stone disease, 41
transplantation activity, 58
Rehabilitation of CAPD patients in the USA, 243
Rejection
differentiation from Cyclosporin A nephrotoxicity, 360
differentiation from Cyclosporin A toxicity by FNAB, 356
early graft rejection after peri-operative transfusion, 291
identification of T-cell subsets, NK cells and monocytes in biopsies using monoclonal antibodies, 315
relationship to plasma suppressive activity, 297
steroid resistance treated by plasmapheresis, 362
T-cell subsets in peripheral blood and transplanted kidney, 309
treatment by ATG, plasmapheresis and by Cyclosporin A, 367
Renal angiography, in transplant renal artery stenosis, 325
Renal artery occlusion, results of surgical correction, 587
Renal Artery Stenosis
experimental studies in pregnant rats, 499, 505
in the presence of contralateral occlusion, 587
reversible deterioration in renal function in transplant patients during captopril therapy, 325
sodium metabolism and hypertension, 483
treated by percutaneous angioplasty, 582
treatment by percutaneous trans-luminal angioplasty, 538
Renal biopsy, findings in steroid resistant transplant rejection, 362
Renal cortical infarction, in experimental nephritis combined with Cyclosporin A, 662
Renal Failure, Acute
captopril induced in patients with transplant renal artery stenosis, 325
captopril related, 535
due to drug-induced interstitial nephritis, 646
incidence and treatment modes, Registry details, 64
prognostic value of Hippuran uptake, 641
renal functional studies in an experimental model and the effect of Verapamil, 650
ultrastructural changes following acute ethylene glycol poisoning, 636
Renal Failure, Chronic, 297
management and results of open heart surgery in renal failure patients, 169
plasma suppression activity, 297
recovery of function after commencing renal replacement therapy, 45
Renal Function
during acute ischaemic renal failure and the effect of Verapamil, 650
in patients with diabetic nephropathy treated by intraperitoneal insulin, 692
Renal Glycosuria
autoantibodies and HLA typing, 681
relationship to diabetes mellitus, 685
Renal haemodynamics, during treatment with enalapril and propranolol, 577
Renal Osteodystrophy
post-transplant osteonecrosis, 331
response to reduction in oral aluminium, 207
Renal perfusion, detected by Hippuran uptake, 641
Renal preservation for transplantation, beneficial effects of Verapamil in perfusion fluid, 650
Renal Stone Disease
activity product ratios, 445
advice on dietary protein intake, 416
critique of therapeutic trials, 380
formation product ratios, 445
in patients with renal tubular acidosis, 473
long-term management of infected stones with hydroxyurea and nitrofurantoin, 466
mechanism of formation of crystals, 386
prevention by restoring normal urinary composition, 381
therapeutic considerations, 376
therapy with bicarbonate or citrate in renal tubular acidosis, 473
thiazide prophylaxis in recurrent stone formers, 477
treatment by diet, thiazides and allopurinol, 434
treatment of cystinuria by Thiola, 427
Renal stone formers, effect of dietary protein on urine composition, 411
Renal tubular acidosis, response of urolithiasis to therapy, 473
Renal Tubular Function  
- in acute renal failure detected by Hippuran uptake, 641
- phosphate handling in idiopathic nephrolithiasis, 450

Renal Vascular Disease  
as a cause of end-stage renal failure, Registry details, 43  
sodium metabolism and hypertension, 483

Renin  
- changes during haemodialysis, 518
- effect of beta-blockade on active renin and pro-renin, 566
- effect of chemical medullectomy in experimental hypertension, 546
- effect of haemodialysis on active and inactive forms, 514
- in nephric and anephric haemodialysis patients, 514
- in pregnancy-induced hypertension, 520
- in toxemia and effect of water immersion, 557
- plasma values in hypertensive children, 551

Renovascular Hypertension  
effect of percutaneous angioplasty, 582
- results in chronic occlusion of renal arteries, 587

Revascularisation of chronically occluding renal arteries, results of surgery, 587
Ribonucleic acid, urinary excretion in idiopathic calcium stone formers, 440
Risk factors in the development of post-transplant osteonecrosis, 331

Sclerosing encapsulating peritonitis, complicating CAPD, 236
Sclerosing peritonitis, incidence in CAPD and relationship to acetate, 241
Serum sickness, experimental, induced by bovine serum albumin, effect of Cyclosporin A, 662

Short Dialysis  
cardiovascular complications, 114
- effect on motor nerve function, 114
- long-term results, 111, 139
- myocardial function in patients with coronary heart disease, 181
- nutritional status, 114

Shwartzman Reaction, as a complication of Cyclosporin A in experimental serum sickness, 662

Single Needle Dialysis  
difficulty during short dialysis, 133
- results and comparison with two needle access, 176

Sodium  
dietary intake and renal handling in calcium stone formers, 455
during experimental hypertension in pregnant rats, 499
erthrocyte co-transport in hypertension, 507
-fractional excretion, in hypertensive children, 551
-in Conn's Syndrome, 484
-in the pathogenesis of hypertension, 483
-intake and urinary calcium excretion, 384
-renal handling after chemical medullectomy, 546
-transmembrane transport in hypertension, 489

Sodium cellulose phosphate, in hypercalciuria, 376
Spontaneous nucleation, in hypercalciuria, 372
Stone dissolution, relationship to urinary saturation, 386

Stone Formation  
effect of acetoxyxamate in recurrent struvite stone formers, 469
-effect of dietary restriction of calcium and oxalate, 401
-effect of hyperuricosuria on calcium oxalate stone formation, 396

Struvite stones, long-term management of infected stones with hydroxyurea and nitrofurantoin, 466
Subclavian catheter, efficiency of haemodialysis, 176
Supersaturation, in urine and relationship to stone formation, 386

Suppressor T-cells  
after blood transfusion, 349
-changes in haemodialysis and CAPD patients, 190
-impair Interleukin-2 production, 349
-induction by viral infections, 265

Survival Statistics  
after living donor transplantation, 24
-comparison between diabetic and non-diabetic patients on haemodialysis, 18
-following first cadaver graft, 24
Survival Statistics, continued
in paediatric patients, 84
method of calculating survival rates, 13
on CAPD with diabetes mellitus, 700
on CAPD, 21, 700
on hospital haemodialysis, 19
on long dialysis schedules, 122
on short dialysis schedules, 117
Sympathetic activity, effect of bromocriptine in haemodialysis patients
with elevated plasma prolactin, 156
Systemic lupus erythematosus,
treatment by plasmapheresis, 629

Tamm-Horsfall mucoprotein, urinary
excretion in idiopathic calcium stone
formers, 440
T-cell function in haemodialysis and
CAPD patients, 230
T-cell Subsets
changes during viral infections after
transplantation, 265
during rejection in peripheral blood
and transplanted kidney, 309
infiltrating grafts during rejection,
315
in haemodialysis and CAPD patients,
190
prognostic value during and after
rejection, 309

Thiazide
in hypercalciuria, 378
in the treatment of calcium stone
disease, 434
prophylaxis in recurrent calcium
stone formers, 477
therapy in calcium stone disease, 460
Thiols, in the treatment of cystinuria,
427
Thrombin, a new inhibitor suitable for
haemodialysis, 144
Thromboendarterectomy, results in
chronic occlusion of renal arteries,
587
Tobramycin, in the treatment of
infected stone disease, 469
Toxaemia, effect of water
immersion on blood
pressure, 557
Transluminal dilatation
incidence of re-stenosis, 538
in renal artery stenosis, 538, 543
Transplant co-ordinator, Registry
information, 59
Transplant rejection, 297, see also
Rejection

Transplantation
anergy as an index for pre-transplant
transfusion, 338
captopril-induced deterioration in
function in patients with arterial
stenosis, 325
causes of graft failure in children, 98
detection of rejection in pancreatic
transplants, 709
duct occlusion for pancreatic trans-
plantation, 711
effect of age on patient survival,
Registry details, 26
effect of blood transfusion on graft
survival, 253
effect of perioperative transfusion
on transplant survival, 291
experience with retransplantation,
284
Fc-receptor blocking antibodies, 305
graft survival in children, 97
incidence of osteonecrosis and
relationship to pulse prednisolone,
101, 331
interval mortality and treatment
change rates, Registry details, 31
investigation of perfusion in
pancreatic transplants, 716
machine perfusion for preservation,
58
minor blood group (Lewis) mis-
mash, 261
pancreatic in patients with diabetes
mellitus, 705, 711
patient mortality after first graft,
Registry details, 24
patient survival, Registry details, 24
potential value of Verapamil in
prevention of ischaemic injury,
650
prednisolone pharmacokinetics and
pharmacodynamics, 286
prednisolone therapy schedules in
children, 105
pre-sensitised patients, 280
pre-transplant blood transfusion
policies, 60
recurrent glomerulonephritis, 75
relationship between calcium
metabolism, vitamin D and PTH,
213
relationship between renal function
and prednisolone side-effects, 286
risk factors at the time of second and
subsequent transplants, 280
source of donors for paediatric
patients, 96
Transplantation, continued
steroid resistant rejection treated by plasmapheresis, 362
survival after living donor graft, Registry details, 27
T-cell subsets in peripheral blood and transplanted kidney during rejection, 309
treatment of CMV infection with hyperimmune globulin, 271
ureteric obstruction detected by ultrasound, 320
viral infections, and changes in T-cell subsets, 265
vitamin D₃ hydroxylation, 213
Treatment change rate, Registry analysis, 28
Triglycerides, during dialysis with heparin and MD-805, 144

Ultrafiltration, in patients on CAPD with sclerosing peritonitis, 241
Ultrasound
findings in analgesic nephropathy, 674
in the detection of transplant ureter obstruction, 320
Uraemia
insulin resistance, 686
response to Hepatitis B vaccination, 161
Urate, relationship of urinary excretion to dietary protein, 411
Urea generation rate, effect of dietary supplements of glycine and methionine, 407
Urea kinetics, to determine haemofiltration schedule in children, 201
Urease inhibition by acetoxyhydroxamate in the treatment of struvite stone formers, 469
Uric acid
effect of diet, thiazides and allopurinol on urinary excretion, 434
excretion and calcium nephrolithiasis, 373, 375
hyperuricosuria and effect on calcium oxalate stone formation, 396
in pregnancy-induced hypertension, 520
tubular reabsorption, 528
Urinary crystallisation inhibitors, effect of dietary protein, 386, 411

Urinary polyanions, as inhibitors of crystallisation, 440
Urinary supersaturation, effect of dietary protein, 411
Urinary Tract Infection
effect of acetoxyhydroxamate in recurrent struvite stone formers, 469
management of infected stone disease with hydroxyurea and nitrofurantoin, 466
Urolithiasis
as a cause of end-stage renal failure, Registry details, 41
relationship between calcium stone disease, urinary calcium excretion and bone mineral content, 460

Vaccination
combined active and passive immunisation in dialysis patients, 167
effective titres following hepatitis B vaccination, 167
hepatitis B in haemodialysis patients, 161
relationship to patients immune status, 168
schedules for hepatitis B vaccination in uraemic and dialysis patients, 166–168
strategy for dialysis units, 166–168

Vascular Access
comparison of single and double needle dialysis, 176
experience during long dialysis schedules, 122
Vascular response, to fluid removed in dialysis patients with coronary heart disease, 181

Vasopressin
effect on water excretion in nephrotic syndrome, 603
in nephrotic syndrome, 607
in toxaemia and effect of water immersion, 557

Verapamil, effect in experimental acute renal failure, 650

Viral Infections
after transplantation, 270
cytomegalovirus, 675
hepatitis A, 61, 675
hepatitis B, 61, 675
hepatitis non A−non B, 61, 675

Virus induced changes in T-cell subsets after transplantation, 265
Vitamin D
1,25(OH)₂ cholecalciferol in idiopathic calcium nephrolithiasis, 450
1,25(OH)₂ cholecalciferol after transplantation, 213
24,25(OH)₂ cholecalciferol after transplantation, 213
25(OH) cholecalciferol after transplantation, 213
stimulation of 1,25(OH)₂ cholecalciferol by PTH, 374
therapeutic effect on post-transplant osteonecrosis, 331

Water metabolism, in the nephrotic syndrome, 603
Wegener’s Granulomatosis, as a cause of end-stage renal failure, Registry details, 45

762